05/06/2025

Paradigm Therapeutics, Inc. Announces Investment by Eshelman Ventures, LLC to Support Completion of Development of SD-101 (Zorblisa™), A Topical Therapy for Treatment Across the Entire Skin Surface of All Subtypes of Epidermolysis Bullosa (EB)

First Topical Therapy Developed to Treat the Wounds and Lesions on the Entire Skin Surface Across All EB Subtypes Funding to be Used for Completion of All Activities to Support Planned NDA Submission in the Second Half of 2025, Along with Plans for Commercialization in the U.S. Mt Pleasant, S.C. (May 6, 2025) — Paradigm […]

08/22/2023

Paradigm Therapeutics Acquires Late Stage “Breakthrough Therapy” Designated Therapy for Treatment of All Subtypes of Epidermolysis Bullosa (EB)

‘Topical Therapy for Treating the Wounds and Lesions on the Entire Skin Surface’ MT PLEASANT, S.C., Aug. 22, 2023 — Paradigm Therapeutics Inc., a biopharmaceutical company, today announced the completion of the acquisition of the worldwide rights of SD-101, a topical whole-body treatment for all subtypes of Epidermolysis Bullosa (EB), from Amicus Therapeutics. Terms of the deal […]